Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inadequate antimicrobial treatment is an independent determinant of hospital mortality, and fungal bloodstream infections are among the types of infection with the highest rates of inappropriate initial treatment. Because of significant potential for reducing high mortality rates, we sought to assess the impact of delayed treatment across multiple study sites. The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality. METHODS: We conducted a retrospective cohort study of patients with candidemia from 4 medical centers who were prescribed fluconazole. Time to initiation of fluconazole therapy was calculated by subtracting the date on which fluconazole therapy was initiated from the culture date of the first blood sample positive for yeast. RESULTS: A total of 230 patients (51% male; mean age +/- standard deviation, 56 +/- 17 years) were identified; 192 of these had not been given prior treatment with fluconazole. Patients most commonly had nonsurgical hospital admission (162 patients [70%]) with a central line catheter (193 [84%]), diabetes (68 [30%]), or cancer (54 [24%]). Candida species causing infection included Candida albicans (129 patients [56%]), Candida glabrata (38 [16%]), Candida parapsilosis (25 [11%]), or Candida tropicalis (15 [7%]). The number of days to the initiation of antifungal treatment was 0 (92 patients [40%]), 1 (38 [17%]), 2 (33 [14%]) or > or = 3 (29 [12%]). Mortality rates were lowest for patients who began therapy on day 0 (14 patients [15%]) followed by patients who began on day 1 (9 [24%]), day 2 (12 [37%]), or day > or = 3 (12 [41%]) (P = .0009 for trend). Multivariate logistic regression was used to calculate independent predictors of mortality, which include increased time until fluconazole initiation (odds ratio, 1.42; P < .05) and Acute Physiology and Chronic Health Evaluation II score (1-point increments; odds ratio, 1.13; P < .05). CONCLUSION: A delay in the initiation of fluconazole therapy in hospitalized patients with candidemia significantly impacted mortality. New methods to avoid delays in appropriate antifungal therapy, such as rapid diagnostic tests or identification of unique risk factors, are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mortality reduction associated with early antimicrobials appears strongest in patients with septic shock, where studies have reported a strong association between time to antibiotics and death in patients with septic shock but weaker associations in patients without septic shock (98,109,110).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [109]
In the citing paper
“Blood cultures take an average of 2–3 days to grow Candida, or longer depending on the species.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Attributable mortality from IC remains high and increases with delays in treatment.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association [167, 171–173].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [171]
In the citing paper
“Multivariate analysis in this study also provided a strong association between delay in therapy and mortality.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [46]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 11×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 2×
“of inappropriate initial treatment [6].”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 5×
“Delaying antifungal therapy appears to be a common practice, and the impact on mortality may be significant [8, 10].”
BackgroundResultInfluentialAttributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“Attributable mortality rates of 49% were also shown among patients with candidemia, compared with uninfected control subjects matched for age, sex, date of hospital admission, underlying diseases, length of time at risk, and type of surgical procedure [5].”
BackgroundPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521 · cited 1×
“[1].”
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437 · cited 2×
“attributable mortality remains 19%–49% [2, 5].”
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331 · cited 10×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“of 8 cases per 100,000 population [2–4].”
Leinberger, D. M., Schumacher, U., Autenrieth, I. B., & Bachmann, T. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.4943-4953.2005 · Cited by 155 · cited 1×
“Development of nonculture methods for the rapid diagnosis of candidemia in patients with BSI may also significantly improve the ability to quickly prescribe appropriate antifungal therapy [19, 20].”
Epidemiology and Prognostic Determinants of Bloodstream Infections in Surgical Intensive Care
Harbarth, S. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.12.1353 · Cited by 135
Cited by
Items 401–500 of 1,000
The Epidemiology of Invasive Candidiasis
Pfaller, M. A., & Diekema, D. J. (2014) · Candida and Candidiasis · doi:10.1128/9781555817176.ch29 · Cited by 33
Luzzati, R., Cavinato, S., Deiana, M. L., Rosin, C., Maurel, C., & Borelli, M. (2014) · Aging Clinical and Experimental Research · doi:10.1007/s40520-014-0251-x · Cited by 33
Lunel, F. M. V., Mennink‐Kersten, M. A. S. H., Ruegebrink, D., van der Lee, H. A. L., Donnelly, J. P., Blijlevens, N. M. A., & Verweij, P. E. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.04.012 · Cited by 36
Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease
van der Elst, K. C. M., Brouwers, C. H. S., van den Heuvel, E. R., van Wanrooy, M. J. P., Uges, D. R. A., van der Werf, T. S., Kosterink, J. G. W., Span, L. F. R., & Alffenaar, J. C. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000235 · Cited by 34
“Older patients are likely to be more fragile and have more comorbid medical conditions, which can possibly influence the treatment outcome.(38,39) We could not demonstrate an effect of the immune status (for the duration of recovery of leukocytes and for the actual leukocyte count) of the patients on the treatment out…”
BackgroundInteractions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance
Hall, G. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5 · Cited by 43
Swoboda, S., Lichtenstern, C., Ober, M. C., Taylor, L. A., Störzinger, D., Michel, A., Brobeil, A., Mieth, M., Hofer, S., Sonntag, H., et al. (2009) · Chemotherapy · doi:10.1159/000264672 · Cited by 34
“] estimate that only in 4.4–7.2p of all subjects candidaemia was the direct cause of death. The time point of initiation of antifungal therapy is most relevant. Delayed antifungal therapy leads to an increase in mortality [ ,”
BackgroundInfluentialMetwally, L. A., Hogg, G., Coyle, P. V., Hay, R. J., Hedderwick, S. A., McCloskey, B., O’Neill, H. J., Ong, G., Thompson, G., Webb, C. H., et al. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47149-0 · Cited by 33
Lunel, F. M. V., Donnelly, J. P., van der Lee, H. A. L., Blijlevens, N. M. A., & Verweij, P. E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02654.x · Cited by 38
“One of the factors that has emerged as pivotal in improving the outcome of patients with invasive candidiasis is the timing of initiation of antifungal therapy [4,5]; these studies have shown that any delay reduces the chance of survival.”
BackgroundAlp, S., Arikan‐Akdagli, S., Gulmez, D., Ascioglu, S., Uzun, O., & Akova, M. (2015) · Mycoses · doi:10.1111/myc.12349 · Cited by 32
INVASIVE CANDIDIASIS IN NON-HEMATOLOGICAL PATIENTS.
Mikulska, M., Bassetti, M., Ratto, S., & Viscoli, C. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.007 · Cited by 37
Invasive fungal infections in liver diseases
Barros, N., Rosenblatt, R. E., Phipps, M. M., Fomin, V. G., & Mansour, M. K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000216 · Cited by 35
“Empiric therapy should be started as soon as the diagnosis is suspected, as early treatment initiation decreases mortality.[114] Echinocandins are recommended as the first line of therapy for candidemia by the Infectious Diseases Society of America except for the management of infections of tissue with low penetration…”
BackgroundRisk prediction for invasive candidiasis
Baronia, A. K., & Marak, K. R. (2014) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.142178 · Cited by 40
Antimicrobial Stewardship in the Emergency Department
Acquisto, N. M., & Baker, S. N. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011400555 · Cited by 32
Collins, C. D., Eschenauer, G. A., Salo, S. L., & Newton, D. W. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00192-07 · Cited by 31
“Recent literature showing a correlation between time to initiation of appropriate antifungal therapy and in-hospital mortality due to candidemia has exemplified the importance of this decision (9, 18).”
BackgroundPediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children
Steinbach, W. J. (2016) · Journal of Fungi · doi:10.3390/jof2010005 · Cited by 38
“Prior studies identified a relationship between the time from onset of signs of infection until initiation of antifungal therapy and mortality [41,42].”
BackgroundLi, Y., Du, M., Chen, L., Liu, Y., & Liang, Z. (2016) · Mycopathologia · doi:10.1007/s11046-016-9997-3 · Cited by 35
Kurland, S., Furebring, M., Löwdin, E., Eliasson, E., Nielsen, E. I., & Sjölin, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02466-18 · Cited by 32
Invasive mold infections: recent advances in management approaches
Chandrasekar, P. H. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902777434 · Cited by 39
“In patients with Candida infections, mortality rates more than doubled when treatment was initiated 2 days after the first positive blood culture as opposed to the same day [99], and adequate treatment has been associated with a 20% decrease in mortality [100].”
BackgroundRecent Progress in the Diagnosis of Pathogenic Candida Species in Blood Culture
Phoompoung, P., & Chayakulkeeree, M. (2016) · Mycopathologia · doi:10.1007/s11046-016-0003-x · Cited by 34
“Candidemia mortality is as high as 40 % and is associated with a lack of appropriate antifungal therapy [4, 5].”
BackgroundAla‐Houhala, M., Valkonen, M. M., Kolho, E., Friberg, N., & Anttila, V.-J. (2019) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2019.1662941 · Cited by 33
“Few earlier retrospective cohort studies have suggested that an early start of an antifungal treatment improves survival in candidemia [26,27].”
BackgroundGuo, Q., Qu, P., Cui, W., Liu, M., Zhu, H., Chen, W., Sun, N., Geng, S., Song, W., Li, X., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08387-6 · Cited by 31
“The latest guidelines of the Surviving sepsis campaign (SCC) have highlighted that the early use of antimicrobial drugs is recommended for adult patients with highly suspected sepsis [21] and timely antifungal therapy is also important [22].”
BackgroundSpontaneous fungal peritonitis: a devastating complication of cirrhosis
Bremmer, D. N., Garavaglia, J. M., & Shields, R. K. (2015) · Mycoses · doi:10.1111/myc.12321 · Cited by 31
Antifungal prophylaxis with micafungin in patients treated for childhood cancer
Kusuki, S., Hashii, Y., Yoshida, H., Takizawa, S., Sato, E., Tokimasa, S., Ohta, H., & Ozono, K. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22140 · Cited by 31
Kludze-Forson, M., Eschenauer, G. A., Kubin, C. J., Della‐Latta, P., & Lam, S. W. (2009) · Medical Mycology · doi:10.3109/13693780903208256 · Cited by 33
The End of an Era in Defining the Optimal Treatment of Invasive Candidiasis
Clancy, C. J., & Nguyen, M. H. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis023 · Cited by 31
Schroeder, J. A., Wilson, C. M., & Pappas, P. G. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.11.007 · Cited by 31
Invasive Candida Infections in the ICU: Diagnosis and Therapy
Hankovszky, P., Társy, D., Öveges, N., & Molnár, Z. (2015) · The Journal of Critical Care Medicine · doi:10.1515/jccm-2015-0025 · Cited by 31
“Several studies have proved that a delayed therapy has a negative effect on survival [5, 53-56].”
BackgroundBataineh, M. T. A., Sutton, D. A., Fothergill, A. W., & Wiederhold, N. P. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.014 · Cited by 30
“Delaying the initiation of antifungal therapy in patients with invasive candidiasis has been shown to result in higher mortality rates.(5,7) The use of systemic antifungals, however, is not without risk due to drug interactions and adverse effects/toxicities”
BackgroundCaspofungin: a review of its characteristics, activity, and use in intensive care units
Hashemian, S. M. R., Farhadi, T., & Velayati, A. A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1794817 · Cited by 31
Knoll, M. A., Ulmer, H., & Lass‐Flörl, C. (2021) · Journal of Fungi · doi:10.3390/jof7010063 · Cited by 33
“In invasive mycoses, early antifungal therapy is crucial for patient survival [13].”
BackgroundInfluentialSteinbrink, J. M., Myers, R. A., Hua, K., Johnson, M. D., Seidelman, J., Tsalik, E. L., Henao, R., Ginsburg, G. S., Woods, C. W., Alexander, B. D., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00924-9 · Cited by 30
Antifungal stewardship in solid organ transplantation
Kriegl, L., Boyer, J., Egger, M., & Hoenigl, M. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13855 · Cited by 31
Candidemias: análisis multicéntrico en 16 hospitales andaluces
Rodríguez-Hernández, M. J., de Pipaón, M. R.-P., Márquez, M., Martín-Rico, P., Castón, J. J., Guerrero-Sánchez, F., Vidal-Verdú, E., Garcia-Figueras, C., del Arco, A., Rodríguez‐Baño, J., et al. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2010.12.003 · Cited by 42
“Insuficiencia renal 23 (17,8) 25 (29) 0,053”
Our 2014 approach to candidaemia
Koehler, P. A., Tacke, D., & Cornely, O. A. (2014) · Mycoses · doi:10.1111/myc.12207 · Cited by 33
Lin, S., Chen, R., Zhu, S., Wang, H., Wang, L., Zou, J., Yan, J., Zhang, X., Farmakiotis, D., Tan, X., et al. (2018) · Mycopathologia · doi:10.1007/s11046-018-0258-5 · Cited by 33
Candida Infections and Modelling Disease
MacCallum, D. M. (2009) · Springer eBooks · doi:10.1007/978-3-642-03150-2_3 · Cited by 32
Garey, K. W., Turpin, R. S., Bearden, D. T., Pai, M. P., & Suda, K. J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.01.001 · Cited by 30
“Previous studies have shown that mortality significantly ncreases in patients who experience a delay in fluconazole n relation to the onset of symptoms [8,9].”
BackgroundMethodInfluentialSelf-citationZanamivir Treatment Is Equally Effective for Both Influenza A and Influenza B
Kawai, N., Ikematsu, H., Iwaki, N., Tanaka, O., Yamanishi, Y., Hirotsu, N., & Kashiwagi, S. (2007) · Clinical Infectious Diseases · doi:10.1086/518385 · Cited by 30
Hung, Y.-P., Lee, C.-C., & Ko, W.-C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869822 · Cited by 29
Emergency medicine updates: Management of sepsis and septic shock
Long, B., & Gottlieb, M. A. (2025) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2025.01.054 · Cited by 34
Invasive candidiasis: future directions in non-culture based diagnosis
Posch, W., Heimdörfer, D., Wilflingseder, D., & Lass‐Flörl, C. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1370373 · Cited by 31
An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia
Cardozo, C., Cuervo, G., Salavert, M., Merino, P., Gioia, F., Fernández‐Ruiz, M., López-Cortés, L. E., Escolà‐Vergé, L., Montejo, M., Muñóz, P., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz491 · Cited by 29
Immunopathogenesis of Emerging Candida auris and Candida haemulonii Strains
Pharkjaksu, S., Boonmee, N., Mitrpant, C., & Ngamskulrungroj, P. (2021) · Journal of Fungi · doi:10.3390/jof7090725 · Cited by 31
“High mortality rates among patients have been associated with a delayed initiation of appropriate antifungal treatment [3,4].”
BackgroundGanguli, A., Lim, J., Mostafa, A., Saavedra, C., Rayabharam, A., Aluru, N. R., Wester, M., White, K., Kumar, J. S., McGuffin, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209607119 · Cited by 29
Moreno, Á., Mah, J., Budvytiene, I., Ho, D. Y., Schwenk, H. T., & Banaei, N. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.00394-24 · Cited by 29
Prattes, J., Schilcher, G., & Krause, R. (2014) · Mycoses · doi:10.1111/myc.12267 · Cited by 35
Early antifungal intervention strategies in ICU patients
Eggimann, P., & Ostrosky-Zeichner, L. L. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e0487 · Cited by 34
Antifungal Therapeutic Drug Monitoring
Lewis, R. E. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0023-9 · Cited by 31
“Similarly, Garey and colleagues [36–38] reported that 55% of patients were underdosed on fluconazole therapy at four large tertiarycare hospitals in the United States because fixed doses were frequently prescribed for obese patients without loading doses (200 or 400 mg/d) or because the patient was infected with an is…”
ResultLeenders, N. H. J., Oosterheert, J. J., Ekkelenkamp, M. B., de Lange, D. W., Hoepelman, A. I. M., & Peters, E. J. G. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.03.009 · Cited by 31
Echinocandin Use in the Neonatal Intensive Care Unit
Caudle, K. E., Inger, A. G., Butler, D. R., & Rogers, P. D. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q346 · Cited by 32
Management of Invasive Candidiasis in the Intensive Care Unit
Playford, E. G., Lipman, J., & Sorrell, T. C. (2010) · Drugs · doi:10.2165/10898550-000000000-00000 · Cited by 30
“Indeed, the critical window of opportunity for antifungal initiation appears to be 12–24 hours following drawing of the first ultimately positive blood culture;([45,56]) given the relatively slow and insensitive diagnostics currently available, in practice, this timeframe is very difficult to achieve.”
Murakami, M., Komatsu, H., Sugiyama, M., Ichikawa, Y., Ide, K., Tsuchiya, R., Kunieda, K., Magishi, A., Akiyama, G., 三浦, 文., et al. (2018) · Journal of General and Family Medicine · doi:10.1002/jgf2.159 · Cited by 31
Neoh, C. F., Slavin, M. A., Chen, S. C. ‐., Stewart, K., & Kong, D. C. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.08.010 · Cited by 32
Agnelli, C., Guimarães, T., Sukiennik, T., Lima, P. R. P., Salles, M. J. C., Breda, G. L., Queiroz‐Telles, F., Magri, M. M. C., Mendes, A. V. A., Camargo, L. F. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9040468 · Cited by 30
Alterations of serum cytokine levels and their relation with inflammatory markers in candidemia
Akın, H., Akalın, H., Budak, F., Ener, B., Ocakoğlu, G., Gürcüoğlu, E., Göral, G., & Oral, H. B. (2015) · Medical Mycology · doi:10.1093/mmy/myu084 · Cited by 28
“Because delayed administration of the antifungal therapy is associated with an increase in mortality, early diagnosis and therapy is crucial for preventing invasive candidiasis [9–11].”
BackgroundContemporary Strategies in the Prevention and Management of Fungal Infections
Koehler, P. A., & Cornely, O. A. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.003 · Cited by 28
MSH2 Gene Point Mutations Are Not Antifungal Resistance Markers in Candida glabrata
Bordallo-Cardona, M. Á., Agnelli, C., Gómez-Nuñez, A., Sánchez-Carrillo, C., Bouza, E., Muñoz, P., Escribano, P., & Guinea, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01876-18 · Cited by 27
“Candida bloodstream infections have been increasing in recent years (1), posing a substantial economic burden for hospitals and high mortality among patients (2, 3).”
BackgroundPini, P., Colombari, B., Marchi, E., Castagnoli, A., Venturelli, C., Sarti, M., & Blasi, E. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.07.007 · Cited by 27
Neofytos, D., Avdic, E., & Magiorakos, A.-P. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6321 · Cited by 28
“27,28 Important considerations with triazole dosing include administration of a loading dose, dose adjustment in patients with renal or hepatic dysfunction, and dose adjustment in the presence of concomitant medications with potential drug–drug interactions.”
Candidemia in the in-patient setting: treatment options and economics
Gagne, J. J., & Goldfarb, N. I. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1643 · Cited by 28
“Two retrospective cohort studies demonstrated that delays in empiric treatment for candidemia are associated with increased rates of mortality [26,27] .”
BackgroundLow but Sufficient Anidulafungin Exposure in Critically Ill Patients
van Wanrooy, M. J. P., Rodgers, M. G. G., Uges, D. R. A., Arends, J. P., Zijlstra, J. G., van der Werf, T. S., Kosterink, J. G. W., & Alffenaar, J. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01607-13 · Cited by 29
“For fluconazole, apart from delayed start of treatment (5), the area under the concentration-time curve (AUC) divided by the MIC has an impact on the mortality of patients with invasive Candida infections (6).”
BackgroundIs Fluconazole or an Echinocandin the Agent of Choice for Candidemia
Eschenauer, G. A., Nguyen, M.-H., & Clancy, C. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015590838 · Cited by 29
“In patients as sick as many of those with candidemia, it is not surprising that rapid initiation of antifungal treatment may be more important than the choice of specific agent.(41,42) In this regard, perhaps the major challenge facing the field is the development of improved diagnostic tests.”
BackgroundLi, C., Wang, H., Yin, M., Han, H., Yue, J.-F., Zhang, F., Shan, T., Guo, H., & Wu, D. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3744 · Cited by 27
Vossen, M. G., Gerges, D., Haidinger, M., Lemmerer, R., Unger, M., Pferschy, S., Lamm, W. W., Maier‐Salamon, A., Jäger, W. R., & Thalhammer, F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02425-16 · Cited by 27
“Fungal sepsis greatly increases morbidity and mortality in critically ill patients (2, 3).”
BackgroundSimor, A. E., Porter, V. R., Mubareka, S., Chouinard, M., Katz, K. C., Vermeiren, C. L., Fattouh, R., Matukas, L. M., Tadros, M., Mazzulli, T., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01387-18 · Cited by 27
“Early initiation of effective antifungal therapy is associated with improved outcomes (2).”
BackgroundAntifungal activity of two oxadiazole compounds for the paracoccidioidomycosis treatment
Rodrigues-Vendramini, F. A. V., Faria, D. R., Arita, G. S., Capoci, I. R. G., Sakita, K. M., Caparroz‐Assef, S. M., Becker, T. C. A., Mendonca, P., Felipe, M. S. S., Svidzinski, T. I. E., et al. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007441 · Cited by 27
Antifungal stewardship with an emphasis on candidaemia
Capoor, M. R., Subudhi, C. P. K., Collier, A., & Bal, A. M. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.05.030 · Cited by 30
Impact of Triazole Therapeutic Drug Monitoring Availability and Timing
McCreary, E. K., Bayless, M. L., Van, A. P., Lepak, A. J., Wiebe, D. A., Schulz, L. T., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01245-19 · Cited by 27
Zaragoza, R., Pemán, J., Quindós, G., Iruretagoyena, J. R., Cuétara, M. S., Ramírez, P., Gómez, M. D., Camarena, J. J., Viudes, A., & Pontón, J. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00183-09 · Cited by 27
“The mortality rate of patients with IC remains excessively high (10) and is associated with difficulty in making a prompt microbiological diagnosis (11) and a delay in antifungal treatment (2, 7).”
BackgroundCoping with Candida Infections
Evans, S. E. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200907-075al · Cited by 32
“Due to the correlation of timely treatment and survival (11, 55, 56), empiric initiation of therapy is broadly endorsed for neutropenic and nonneutropenic patients suspected of having invasive candidiasis (23, 25, 26).”
BackgroundInfluentialLavergne, R., Chauvin, P., Valentin, A., Fillaux, J., Roques-Malecaze, C., Arnaud, S., Ménard, S., Magnaval, J., Berry, A., Cassaing, S., et al. (2013) · Medical Mycology · doi:10.3109/13693786.2012.762607 · Cited by 26
Fisher, B. T., Boge, C. L. K., Xiao, R., Shuster, S., Chin‐Quee, D. S., Allen, J. E., Shaheen, S. K., Hayden, R. T., Suganda, S., Zaoutis, T. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab928 · Cited by 26
Candida haemulonii complex, an emerging threat from tropical regions?
Françoise, U., Desnos‐Ollivier, M., Govic, Y. L., Sitbon, K., Valentino, R., Peugny, S., Chouaki, T., Mazars, E., Paugam, A., Nicolas, M., et al. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0011453 · Cited by 26
“This strategy could limit the delay before initiation of appropriate treatment, which is strongly correlated with mortality in candidemia [31,35].”
BackgroundWang, X., Fu, Y., Wang, R., Li, L., Cao, Y., Chen, Y., Zhao, H., Zhang, Q., Wu, J., Weng, X., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098110 · Cited by 26
“Optimal treatment is of importance to reduce mortality [3,4].”
BackgroundPebotuwa, S., Kochan, K., Peleg, A. Y., Wood, B. R., & Heraud, P. (2020) · Molecules · doi:10.3390/molecules25071551 · Cited by 29
Vázquez, J. A., & Sobel, J. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_11 · Cited by 37
Diagnostics and Susceptibility Testing in Aspergillus
Bernal-Martínez, L., Alastruey-Izquierdo, A., & Cuenca-Estrella, M. (2016) · Future Microbiology · doi:10.2217/fmb.15.140 · Cited by 25
Drug resistance in fungi - an emerging problem
Chakrabarti, A. (2011) · Cited by 27
Farina, C., Perin, S., Andreoni, S., Conte, M., Fazii, P., Lombardi, G., Manso, E., Morazzoni, C., & Sanna, S. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02166.x · Cited by 28
Reactivity of the 1,3‐β‐D‐glucan assay during bacteraemia: limited evidence from a prospective study
Ráčil, Z., Kocmanová, I., Tošková, M., Winterová, J., Lengerová, M., Timilsina, S., & Mayer, J. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02210.x · Cited by 25
Candidaemia in a paediatric centre and importance of central venous catheter removal
Öncel, E. K., Kara, A., Özsürekçi, Y., Arıkan-Akdağlı, S., Cengiz, A. B., Ceyhan, M., Gür, D., Çelik, M., & Parlakay, A. Ö. (2015) · Mycoses · doi:10.1111/myc.12288 · Cited by 26
New Antimicrobial Agents for Use in the Intensive Care Unit
Ritchie, D. J., Alexander, B. T., & Finnegan, P. M. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.010 · Cited by 25
Ellis, M. E., Bernsen, R. M. D., Alizadeh, H., Kristensen, J., Hedström, U., Poughias, L., Bresnik, M., Alessa, A., & Stevens, D. A. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.012401-0 · Cited by 25
Epidemiología de las candidiasis invasoras en población pediátrica y adulta
del Palacio, A., Villar, J., & Alhambra, A. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70002-6 · Cited by 35
Fungemia in non-HIV-infected patients: a five-year review
Anunnatsiri, S., Chetchotisakd, P., & Mootsikapun, P. (2008) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2008.04.009 · Cited by 29
Borman, A. M., Székely, A., Palmer, M. D., & Johnson, E. M. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00913-12 · Cited by 25
“Accumulating evidence underscores the important role of early and appropriate antifungal therapy in clinical outcome for patients with candidiasis (12, 18, 20, 21, 23) Since the in vitro patterns of antifungal susceptibility are known to vary substantially between different Candida species (6, 30, 31), informed therap…”
BackgroundKovanda, L. L., Maher, R., & Hope, W. W. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1185361 · Cited by 24
Beyda, N. D., Amadio, J., Rodriguez, J. R., Malinowski, K., Garey, K. W., Wanger, A. R., & Ostrosky-Zeichner, L. L. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00471-18 · Cited by 24
“Bloodstream infections caused by Candida species are associated with high mortality, and early diagnosis and prompt initiation of antifungal treatment are essential to improving patient outcomes (1, 2).”
BackgroundSelf-citationDeclining Incidence of Candidemia in a Tertiary Inpatient Pediatric Population
Ota, K. V., & McGowan, K. L. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.06346-11 · Cited by 24
“In the adult literature, early initiation of effective antifungal therapy (5, 11) and timely removal of central venous catheters (8, 19) are strategies that appear to mitigate mortality in some populations.”
BackgroundDirect antifungal susceptibility testing of positive Candida blood cultures by sensititre YeastOne.
Avolio, M., Grosso, S., Bruschetta, G., Rosa, R. D., & Camporese, A. (2009) · PubMed · Cited by 24
Candidainfections in the intensive care unit: epidemiology, risk factors and therapeutic strategies
Bassetti, M., Righi, E., Tumbarello, M., Biagio, A. D., Rosso, R., & Viscoli, C. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.5.875 · Cited by 26
All You Need to Know and More about the Diagnosis and Management of Rare Mold Infections
Hoenigl, M., Levitz, S. M., Schuetz, A. N., Zhang, S. X., & Cornely, O. A. (2021) · mBio · doi:10.1128/mbio.02920-20 · Cited by 24
Darouiche, R. O. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.013 · Cited by 23
Sganga, G., Wang, M., Capparella, M. R., Tawadrous, M., Yan, J. L., Aram, J. A., & Montravers, P. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03617-9 · Cited by 25
Vargas-Espíndola, L. A., Cuervo, S. I., Enciso-Olivera, J. L., Gómez-Rincón, J. C., Cetina, L. P. J., Sánchez, R., García-Guzmán, K., López-Mora, M. J., Álvarez, C., Cortés, J. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9040400 · Cited by 26
“As mortality higher than 60% has been reported in patients without antifungal treatment [45], recent studies suggest that the early initiation of antifungal treatment has been related to decreased mortality, both early and late [2,44,46,47], as well as the use of echinocandins as a first-line treatment having an impac…”
BackgroundTreatment of critically ill patients with candidemia
Mensa, J., Pitart, C., & Marco, F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70007-4 · Cited by 26
“[3], similar results were obtained in a series of 192 patients with candidemia treated with fluconazole.”
ResultUsing sweeping-micellar electrokinetic chromatography to determine voriconazole in patient plasma
Lin, S.-C., Lin, S., Chen, J., & Kuo, C. (2010) · Talanta · doi:10.1016/j.talanta.2010.05.027 · Cited by 24
Initial antifungal strategy does not correlate with mortality in patients with candidemia
Murri, R., Scoppettuolo, G., Ventura, G., Fabbiani, M., Giovannenze, F., Taccari, F., Milozzi, E., Posteraro, B., Sanguinetti, M., Cauda, R., et al. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2527-2 · Cited by 24
“Appropriate and timely antifungal therapy is correlated with better outcomes [2–5].”
González-Lara, M. F., Torres‐González, P., Cornejo‐Juárez, P., Velázquez-Acosta, C., Martínez‐Gamboa, A., Rangel‐Cordero, A., Bobadilla-del-Valle, M., Ostrosky-Zeichner, L. L., Ponce‐de‐León, A., & Sifuentes‐Osornio, J. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2846-2 · Cited by 24
“It has been previously demonstrated that mortality increases wih each subsequent day that empirical therapy is delayed [34, 35].”
BackgroundCurrent and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship
Timbrook, T. T., Spivak, E. S., & Hanson, K. E. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.05.004 · Cited by 23
Metadata
- Authors
- Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T.
- Affiliations
- University of Houston (US)
- University of New Mexico (US)
- Baptist Memorial Health Care (US)
- University of Tennessee Health Science Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Oregon State University (US)
- Corresponding author
- Garey, Kevin W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 43
- Issue
- 1
- Pages
- 25-31
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2164001967
- Semantic Scholar
- e1a67fd5e540307550577ea7a071370b075e943f
- Cited by
- 1,171
- References
- 20
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 31 · 2023: 31 · 2022: 49 · 2021: 67 · 2020: 51 · 2019: 51 · 2018: 62 · 2017: 66 · 2016: 61 · 2015: 74 · 2014: 87 · 2013: 83 · 2012: 77
- FWCI
- 35.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Enzon Pharmaceuticals
- University of Houston
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, fluconazole, treatment delay, mortality, fungemia, Candida albicans, APACHE II score, mortality risk factors, hospitalized patients, Candida tropicalis, Candida parapsilosis, Candida glabrata, diabetes mellitus, cancer patients, sepsis
- MeSH terms
- Adult, Aged, Antifungal Agents, Candidiasis, Female, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, Time Factors, Cohort Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.